Physician profile
Lori Mitchell
NPI 1710365655
$1,480.48
in general payments reported to CMS, 2019-2025
15 companies · $489 in 2025
The $489 reported for 2025 was more than what 93% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.93 · 2021: $12.16 · 2022: $135 · 2023: $293 · 2024: $538 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,319.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $369.61 | 2024-2025 | |
| Supernus Pharmaceuticals, INC. | $286.53 | 2023-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $186.90 | 2021-2024 | Dyanavel Xr, Quillichew Er, Quillivant |
| Corium, LLC | $172.25 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $103.79 | 2022-2024 | |
| Seqirus USA INC | $81.66 | 2022-2025 | Flucelvax, Flucelvax Quadrivalent |
| Merck Sharp & Dohme LLC | $73.03 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Collegium Pharmaceutical, INC. | $53.28 | 2025 | Jornay Pm |
| Pfizer INC. | $35.49 | 2025 | |
| Phadia US INC. | $23.10 | 2025 | Immunocap |
| Kaleo, INC. | $21.24 | 2022 | |
| Sanofi Pasteur INC. | $20.06 | 2023 | |
| Alk-Abello, INC | $19.63 | 2025 | Neffy |
| Glaxosmithkline, LLC. | $17.04 | 2023 | Bexsero |
| Pharming Healthcare, INC. | $16.87 | 2023 | Ruconest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.